Compare HFWA & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HFWA | ABUS |
|---|---|---|
| Founded | 1927 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 748.4M | 848.1M |
| IPO Year | N/A | N/A |
| Metric | HFWA | ABUS |
|---|---|---|
| Price | $25.37 | $4.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $29.33 | $5.00 |
| AVG Volume (30 Days) | 187.7K | ★ 1.0M |
| Earning Date | 01-22-2026 | 11-13-2025 |
| Dividend Yield | ★ 3.80% | N/A |
| EPS Growth | ★ 53.03 | N/A |
| EPS | ★ 1.65 | N/A |
| Revenue | ★ $232,877,000.00 | $14,606,000.00 |
| Revenue This Year | $21.61 | $125.30 |
| Revenue Next Year | $29.10 | N/A |
| P/E Ratio | $15.29 | ★ N/A |
| Revenue Growth | 14.16 | ★ 116.64 |
| 52 Week Low | $19.84 | $2.71 |
| 52 Week High | $26.58 | $5.10 |
| Indicator | HFWA | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 72.07 | 61.16 |
| Support Level | $24.01 | $4.43 |
| Resistance Level | $25.53 | $4.63 |
| Average True Range (ATR) | 0.56 | 0.19 |
| MACD | 0.18 | 0.04 |
| Stochastic Oscillator | 91.46 | 91.03 |
Heritage Financial Corp is a bank holding company. The company through its subsidiary provides commercial lending and deposit relationships with small businesses and their owners in its market areas and attracts deposits from the general public. It accepts various deposit products, such as noninterest demand accounts, money market accounts, savings accounts, and certificates of deposit. Besides, the Bank also makes real estate construction loans, land development loans, and consumer loans, and originates first mortgage loans on residential properties mainly located in its market area. Geographically, all the business activity functions through the region of the United States.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.